Among these, m6A readers IMP1/2/3 proteins are a well-established class of insulin growth factor-binding protein families; m6A modulator dysregulation has been recently associated with tumor aggressiveness and clinical prognostic survival in various cancers, including hepatocellular carcinoma (HCC), gastric cancer, pancreatic cancer, and CRC [11–14]. This evidence concerns the gene METTL3 and hepatocellular carcinoma.